Erlotinib - CAS 183321-74-6
Catalog number: 183321-74-6
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C22H23N3O4
Molecular Weight:
393.44
COA:
Inquire
Targets:
EGFR
Description:
Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
CP358774, NSC 718781
MSDS:
Inquire
1. Chimerically designed HDAC- and tyrosine kinase inhibitors. A series of erlotinib hybrids as dual-selective inhibitors of EGFR, HER2 and histone deacetylases
Thomas Beckers, Siavosh Mahboobi,* Mathias Schmidt*. Med. Chem. Commun., 2012, 3, 829–835
Linking the erlotinib substructure with an N-(2-aminophenyl)-3-(1-sulfonyl-1H-pyrrol-3-yl)acrylamide results in inhibition of nuclear extract HDAC and HDAC 1 in the micromolar range (compound 10). The potency of the phenylenediamine inhibitors depends on the nature of the central linking system between the phenylenediamine and the erlotinib scaffold. In this series of HDAC inhibitors the compounds harboring an oxymethyl-benzamide (9a, 9b) or a sulfonylpyrrol-acrylamide (10) show an IC50 of inhibition of rHDAC 1 below 100 nM. This methylene-benzamide motif is also found in two benzamides in advanced clinical development named entinostat (4) and mocetinostat (5) (Fig. 1). The same magnitude of potency is seen in the sulfonylpyrrol-acrylamide (10). Changing the phenylenediamine structure motif to a hydroxamic acid leads to compound 11 with an inhibition of nuclear extract HDAC and HDAC 1 in the low nanomolar range. The IC50 values show approximately 10 times higher potency towards nuclear extract HDAC and rHDAC 1 than the reference compound SAHA.
2. Discovery of 3,3a,4,5-tetrahydro-2 -benzo[g ] indazole containing quinoxaline derivatives as novel EGFR/HER-2 dual inhibitors
Xi Zong, Jin Cai, Junqing Chen, Chunlong Sun, Lushen Li and Min Ji*. RSC Adv.,2015, 5,24814–24823
In this work, a series of pyrazole–quinoxaline derivatives that potentially function as inhibitors of EGFR and HER-2 kinases have been synthesized, and most of them exhibited potent affinity for EGFR or HER-2 kinase as well as excellent anti-proliferative activity. Compound 4l showed excellent EGFR/HER-2 inhibitory activities and better antiproliferative activity against A549 and MCF-7 cell lines than Erlotinib. After analysis of the binding models of compounds 4l and 4x with EGFR, it was found that the models of compounds 4l or 4x in complex with the ATP binding site were similar to that of Erlotinib. The quinoxaline moiety might play a crucial role in the compounds’ EGFR inhibition activity by forming π-πinteractions and hydrogen bonding interactions with the residues in the binding pocket. Finally, QSAR models were built with the activity data and binding conformations to begin our work in this paper, as well as to provide a reliable tool for the reasonable design and synthesis of potent tyrosine kinase inhibitors. In conclusion, the preliminary evaluation results demonstrated that the newly developed tricyclic heterocycle-containing pyrazoles combined with a thiazolo quinoxaline ring, acting as potent dual EGFR and HER-2 inhibitors, may possess therapeutic potential for cancer treatment.
3. Fabrication of PVCL-co-PMMA nanofibers with tunable volume phase transition temperatures and maintainable shape for anti-cancer drug release
Zaiqian Yu, Hongjuan Gu, Dongyan Tang*. RSC Adv.,2015, 5, 64944–64950
As to Erlotinib wrapped PVCL electrospinning materials, nanofibers swelled at temperature that below LCST and deswelled that above it. The sizes of the pores on the electrospinning mats would shrink and expand accordingly. Erlotinib particles could be of acid soluble and of slow dissolution behavior at neutral pH values. Thus the drug particles would penetrate the pores when the nanofibers were in shrinking state, and while would be trapped when the nanofibers were in expanding state. As reflected by Fig. 10(C) and (D), drug released at a faster rate at temperature that above the LCST values than that below one, indicating the positive relation of releases to temperatures. And although the drug particles were in trapped state at the “off” status, the nanofibers were still in more hydrophilic state while below the LCST values, and thus the gels were penetratable for drug molecules, so the drug still could be released.
4. A novel strategy for targeting photodynamic therapy Molecular combo of photodynamic agent zinc(II) phthalocyanine and small molecule target-based anticancer drug erlotinib
Feng-Ling Zhang, Qi Huang, Ke Zheng, Jun Li, Jian-Yong Liu* and Jin-Ping Xue*. Chem. Commun., 2013, 49, 9570—9572
In summary, we have synthesised and characterised two zinc(II) phthalocyanine–erlotinib conjugates and evaluated their in vitro photodynamic activities and selective affinity toward HepG2 cancer cells and A431 tumour tissues. The conjugates contain both photodynamic and targeting anti-cancer therapy agents which are covalently linked and function in a cooperative manner. The introduction of the erlotinib moiety can enhance the specificity of phthalocyanine units to HepG2 cancer cells and A431 tumour tissues. The IC50 value of the conjugates is as low as 0.01 mM toward the HepG2 cells, which is equivalent to that of the reference compound 4 without the erlotinib derivative. The tumour/skin ratio of the conjugate is actually about 5-fold higher than that of reference 4. The overall results show that the conjugates are highly promising antitumour agents for dual targeting and photodynamic therapy. This may provide a novel targeting strategy for PDT, as well as other cancer therapy modalities.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related EGFR Products


CAS 1204313-51-8 Icotinib (Hydrochloride)

Icotinib (Hydrochloride)
(CAS: 1204313-51-8)

CAS 451492-95-8 MP-412

MP-412
(CAS: 451492-95-8)

MP-412 (AV-412) is a second-generation, orally bioavailable dual kinase inhibitor with potential antineoplastic activity. EGFR/HER2 inhibitor AV-412 binds to an...

Naquotinib mesylate
(CAS: 1448237-05-5)

Naquotinib is irreversible, third-generation, epidermal growth factor receptor (EGFR) inhibitor with IC50 value of 70 nM for NCI-H1650 cell growth. It can coval...

CO-1686 hydrobromide
(CAS: 1446700-26-0)

CO-1686 hydrobromide is the hydrobromide salt form of CO-1686. CO-1686, also called as Rociletinib, is an oral tyrosine kinase inhibitor that irreversibly and s...

CAS 497839-62-0 AEE-788

AEE-788
(CAS: 497839-62-0)

AEE-788 is an orally bioavailable multiple-receptor tyrosine kinase inhibitor. AEE788 inhibits phosphorylation of the tyrosine kinases of epidermal growth facto...

MTX-211
(CAS: 1952236-05-3)

MTX-211 is a dual inhibitor of EGFR and PI3K, which plays important roles in the progression of KRAS mutant colorectal cancer. MTX-211 has the potential for the...

Selatinib
(CAS: 1275595-86-2)

Selatinib is a Epidermal growth factor receptor(EGFR) and ERbB-2 receptor antagonist as an analog of the quinazoline lapatinib with potential antineoplastic act...

CAS 487-52-5 Butein

Butein
(CAS: 487-52-5)

Butein, a plant polyphenol isolated from Rhus verniciflua, is able to inhibit the activation of protein tyrosine kinase, NF-κB and STAT3, also inhibits EGFR. Th...

CAS 1092364-38-9 Poziotinib

Poziotinib
(CAS: 1092364-38-9)

Poziotinib, also known as HM781-36B and NOV120101, is an orally bioavailable, quinazoline-based pan epidermal growth factor receptor (EGFR or HER) inhibitor wit...

CAS 194423-06-8 CL-387785

CL-387785
(CAS: 194423-06-8)

CL-387785, also known as EKI-785, is an irreversible inhibitor of EGF-receptor (EGFR) kinase activity in vivo (IC50 = 250-490 pM). CL-387785 covalently bound t...

CAS 231277-92-2 Lapatinib

Lapatinib
(CAS: 231277-92-2)

Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively.

CAS 1375465-09-0 CNX-2006

CNX-2006
(CAS: 1375465-09-0)

CNX-2006 is a potent, mutant-selective EGFR inhibitor with excellent in vitro activity in cells with activating EGFR mutations, as well as in cells harbouring t...

CAS 845272-21-1 Varlitinib

Varlitinib
(CAS: 845272-21-1)

Varlitinib, also known as ARRY-543, is an orally bioavailable inhibitor of the epidermal growth factor receptor family with potential antineoplastic activity. V...

CAS 139087-53-9 AG 494

AG 494
(CAS: 139087-53-9)

AG-494 is a EGFR (epidermal growth factor receptor) kinase inhibitor with IC50 value of 0.7 μM. It is selective over ErbB2, PDGFR and insulin receptor kinase (I...

CAS 1374640-70-6 CO1686

CO1686
(CAS: 1374640-70-6)

CAS 196612-93-8 Falnidamol

Falnidamol
(CAS: 196612-93-8)

Falnidamol, also known as BIBX 1382, is a pyrimido-pyrimidine with antitumor activity. BIBX 1382 inhibits the intracellular tyrosine kinase domain of the Epider...

CAS 610798-31-7 Icotinib

Icotinib
(CAS: 610798-31-7)

Icotinib Hydrochloride (BPI-2009H), or Icotinib, is a highly selective, first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI).

EGF816 mesylate
(CAS: 1508250-72-3)

EGF816 mesylate is the mesylate salt of EGF816 which is a covalent mutant-selective EGFR inhibitor and potently inhibits the T790M.

CAS 153436-54-5 PD-153035

PD-153035
(CAS: 153436-54-5)

PD153035 is a ATP-competitive EGFR inhibitor with an IC50 and Ki of 25 and 6 pM. PD153035 effectively blocks the enhancement of mitogenesis, induction of early ...

CAS 897383-62-9 AST-1306

AST-1306
(CAS: 897383-62-9)

AST-1306 functions as an irreversible inhibitor, most likely through covalent interaction with Cys797 and Cys805 in the catalytic domains of EGFR and ErbB2, res...

Chemical Structure

CAS 183321-74-6 Erlotinib

Quick Inquiry

Verification code

Featured Items